Clinical Trial Materials

IRBs Need More Monitoring

February 23, 2023

GAO calls for more oversight of institutional review boards in clinical trials.

Boehringer Ingelheim, 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

January 13, 2023

It is intended to identify the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning.

Catalent Completes Expansion of Clinical Supply Facility

December 01, 2022

Catalent has completed the expansion of its clinical supply facility located in Shanghai, China.

Pfizer, Merck KGaA, and Immutep Enter into Second Clinical Trial Collaboration Agreement

November 30, 2022

The agreement will see Immutep and Merck KGaA, Darmstadt, Germany jointly fund the INSIGHT-005 study.

CellVax and Theragent Form Manufacturing Pact for Novel Cancer Immunotherapy Drug Candidate

November 17, 2022

CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.

Otsuka Pharmaceutical and Osaka University Enter Exclusive License Agreement

April 20, 2022

Otsuka Pharmaceutical and Osaka University have entered an exclusive license agreement on a new anti-tumor antibody.

Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care

March 25, 2022

Huma has acquired AstraZeneca’s digital health platform, and AstraZeneca has become a shareholder of Huma in a partnership to accelerate digital-first patient care.

Selecting and Optimizing the Right Manufacturing Partner

March 02, 2022

Optimizing the use of partners for clinical trials depends on selecting the right contractor.

Insights into Outsourced vs. In-house Clinical Trial Services

March 02, 2022

Capacity concerns and regulatory compliance considerations will drive the decision about outsourcing the manufacture of clinical trial materials.

Recipharm Acquires Portuguese CDMO, GenIbet, Boosting Biologics Offering

February 01, 2022

Recipharm will build up its biologics service offering with the acquisition of GenIbet.